MktsMarkets

Minerva Neurosciences, Inc
NASDAQ: NERVKey statistics
NERV News
Stories mentioning NERV from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||||
| Research & Development | 5,255 | 2,174 | 925.00 | 1,298 | 1,362 | 1,984 | 1,888 | 3,860 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 16,672 | 4,982 | 2,844 | 3,374 | 3,903 | 4,521 | 4,367 | 6,278 |
| Operating Income (Loss) | (16,672) | (4,982) | (2,844) | (3,374) | (3,903) | (4,521) | (4,367) | (6,278) |
| Interest Income | 630.00 | 546.00 | 107.00 | 137.00 | 158.00 | 239.00 | 314.00 | 361.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (125,404) | (283,667) | (2,744) | (3,259) | (3,753) | (4,272) | 22,513 | (8,233) |
| Earnings Per Share (Basic) | (2.86) | (33.51) | (0.36) | (0.43) | (0.50) | (0.56) | 2.97 | (1.09) |
| Earnings Per Share (Diluted) | (2.86) | (33.51) | (0.36) | (0.43) | (0.50) | (0.56) | 2.97 | (1.09) |
| Weighted Average Shares Outstanding (Basic) | 43,900 | 8,464 | 7,569 | 7,569 | 7,569 | 7,569 | 7,569 | 7,569 |
| Weighted Average Shares Outstanding (Diluted) | 43,900 | 8,464 | 7,569 | 7,569 | 7,569 | 7,574 | 7,569 | 7,569 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NERV
Minerva Neurosciences, Inc (NASDAQ: NERV) is a stock listed on the Nasdaq Stock Market under the ticker symbol NERV. It last traded at $2.27 (Oct 26, 2026, 1:22 PM ET), down 1.3% on the day. That gives Minerva Neurosciences a market capitalisation of $109.8M.
Over the past 52 weeks NERV has traded between $2.24 and $8.80.
For the quarter ended Mar 31, 2026 it reported a net loss of $125.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$125.4M |
| Dec 31, 2025 | — | -$283.7M |
| Sep 30, 2025 | — | -$2.7M |
| Jun 30, 2025 | — | -$3.3M |
From Minerva Neurosciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…